Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1
- PMID: 14744540
- DOI: 10.1016/j.canlet.2003.09.031
Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1
Abstract
We describe here the establishment of a new synovial sarcoma cell line, SYO-1, derived from a biphasic synovial sarcoma that developed in the groin of a 19-year-old female. The cell line was maintained for more than 70 passages (more than 24 months) in vitro. The SYO-1 cells in monolayer culture exhibited a spindle shape without conspicuous pleomorphism. Immunohistochemically, the cells were positive for vimentin, type IV collagen, S-100, mdm2, bcl-2, c-Met and c-Kit. Tumors developed by their implantation in nude mice histologically showed biphasic features that were composed of areas of fascicles of spindle cells and areas of compact proliferation of polygonal to ovoid cells, which occasionally formed epithelial plaque and expressed cytokeratin and EMA. SYO-1 cells harbored the characteristic t(X;18)(p11.2;q11.2) translocation by chromosome analysis and SYT-SSX2 chimeric transcript by RT-PCR. The SYO-1 cells, the first characterized cell line derived from biphasic synovial sarcoma retaining the characteristic genetic and phenotypic features of the tumor, will be useful for various investigations on synovial sarcoma, especially for its epithelial differentiation.
Similar articles
-
Establishment of a new human synovial sarcoma cell line, FU-SY-1, that expresses c-Met receptor and its ligand hepatocyte growth factor.Int J Oncol. 2002 Jul;21(1):17-23. Int J Oncol. 2002. PMID: 12063544
-
Establishment and characterization of a new synovial sarcoma cell line, SN-SY-1: special reference to bcl-2 protein and SYT-SSX1 hybrid transcripts.Int J Cancer. 1997 Sep 17;72(6):995-1002. doi: 10.1002/(sici)1097-0215(19970917)72:6<995::aid-ijc13>3.0.co;2-4. Int J Cancer. 1997. PMID: 9378564
-
Detection of SYT-SSX fusion transcripts in archival synovial sarcomas by real-time reverse transcriptase-polymerase chain reaction.J Mol Diagn. 2002 Feb;4(1):59-64. doi: 10.1016/S1525-1578(10)60681-2. J Mol Diagn. 2002. PMID: 11826189 Free PMC article.
-
SYT-SSX fusion genes in synovial sarcoma of the thorax.Lung Cancer. 2004 Jun;44(3):391-7. doi: 10.1016/j.lungcan.2003.11.011. Lung Cancer. 2004. PMID: 15140553 Review.
-
Primary pulmonary synovial sarcoma confirmed by molecular detection of SYT-SSX1 fusion gene transcripts: a case report and review of the literature.Jpn J Clin Oncol. 2005 May;35(5):274-9. doi: 10.1093/jjco/hyi073. Epub 2005 May 6. Jpn J Clin Oncol. 2005. PMID: 15879502 Review.
Cited by
-
Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma.Oncotarget. 2017 Nov 28;8(65):109587-109595. doi: 10.18632/oncotarget.22730. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312631 Free PMC article.
-
Anti‑proliferative activity of epigallocatechin‑3‑gallate and silibinin on soft tissue sarcoma cells.Mol Med Rep. 2017 Jan;15(1):103-110. doi: 10.3892/mmr.2016.5969. Epub 2016 Nov 28. Mol Med Rep. 2017. PMID: 27909727 Free PMC article.
-
Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.Cancer Sci. 2020 Feb;111(2):429-440. doi: 10.1111/cas.14271. Epub 2019 Dec 30. Cancer Sci. 2020. PMID: 31808966 Free PMC article.
-
Analysis of mutations in primary and metastatic synovial sarcoma.Oncotarget. 2018 Dec 7;9(96):36878-36888. doi: 10.18632/oncotarget.26416. eCollection 2018 Dec 7. Oncotarget. 2018. PMID: 30627328 Free PMC article.
-
Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.Cell Death Dis. 2018 May 1;9(5):446. doi: 10.1038/s41419-018-0474-4. Cell Death Dis. 2018. PMID: 29670090 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous